BMC Cancer最新文献

{"title":"A nomogram model to predict postoperative delirium in esophageal cancer patients undergoing esophagectomy.","authors":"Chen Chen, Jiayu Wang, Yang Li","doi":"10.1186/s12885-025-14478-1","DOIUrl":"10.1186/s12885-025-14478-1","url":null,"abstract":"<p><strong>Background: </strong>Postoperative delirium (POD) after esophagectomy is one of the most serious complications for cases with esophageal cancer (EC). This study determined to obtain predictive factors for POD and develop a nomogram model to predict the occurrence of POD among EC patients.</p><p><strong>Methods: </strong>LASSO and multivariate logistic regression analyses were utilized to identify potential predictive factors. A nomogram model was developed based on the results of multivariate logistic regression analysis.</p><p><strong>Results: </strong>Totally, 924 EC patients undergoing esophagectomy were included, and 157 (16.99%) patients developed POD. Results of LASSO and multivariate logistic analyses showed that age > 70 years, use of penehyclidine hydrochloride, open surgery, preoperative lymphocyte ≤ 1.45*10⁹/L, preoperative albumin ≤ 43.6 g/L, preoperative prognostic nutritional index (PNI) ≤ 50.9, preoperative neutrophil-to-lymphocyte ratio (NLR) > 2.33, preoperative platelet-to-white cell ratio (PWR) ≤ 34.97, and postoperative PNI ≤ 39.40 were independent risk factors for POD. This nomogram model showed a good predictive ability with a C-index value of 0.832 (95% CI: 0.797-0.867). The calibration curve suggested that the predicted results of this nomogram model were in concordance with the actual results. The decision curve analysis (DCA) of this nomogram indicated that there were net benefits for predicting POD.</p><p><strong>Conclusion: </strong>This nomogram model helps clinicians to predict the occurrence of POD in patients with EC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1082"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing myelofibrosis burden on QoL and productivity from healthcare personnel and patient perspectives in India.","authors":"Prantar Chakrabarti, Abhay Bhave, Claire Harrison, Tulika Seth, Vikram Mathews, Disha Shetty","doi":"10.1186/s12885-025-14324-4","DOIUrl":"10.1186/s12885-025-14324-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1097"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of barriers to cervical cancer screening at primary health care centers in Makurdi, North-Central Nigeria: a mixed-methods study.","authors":"Omoregie Irowa, Olumide Stephen Adeyeye, Otobo Innocent Ujah, Paul Ejeh Ogwuche, Adah Emmanuel Otache, Chiahemba Joseph Agulebe","doi":"10.1186/s12885-025-14494-1","DOIUrl":"10.1186/s12885-025-14494-1","url":null,"abstract":"<p><strong>Background: </strong>The major burden of cervical cancer occurs in low income countries in sub-Saharan Africa despite efforts to improve uptake of cervical cancer screening. This study aims to assess the gaps and barriers to cervical cancer screening at primary health care centers in Makurdi, North Central Nigeria.</p><p><strong>Methods: </strong>This was a convergent parallel mixed method approach involving a cross-sectional study of 288 women aged 25-65 years and 30 key informant interviews (KIIs) with healthcare workers, women and male partners across five primary healthcare centers in Makurdi. Data were collected using an interviewer-guided online questionnaire (Kobo Collect) and a semi-structured interview guide. The quantitative data were analyzed with the Statistical Package for the Social Sciences (SPSS) version 20 (Armonk, NY: IBM Corporation), and the qualitative data were transcribed verbatim using Turboscribe.ai. and analyzed thematically with both inductive and deductive approaches to identify key patterns and themes.</p><p><strong>Results: </strong>Female participants were mostly between the ages of 25-34 years (76.4%), traders (41%), with secondary education (46.2%) and with an average monthly income of less than 30,000 naira (50.7%). The gaps limiting cervical cancer screening at primary healthcare centers include no routine cervical cancer screening, lack of trained manpower, lack of equipment, lack of training for hospital staff, inadequate knowledge among healthcare workers, and inadequate funding. The barriers to cervical cancer screening include poor knowledge of cervical cancer and cervical cancer screening, the high cost of cervical cancer screening, no knowledge of where to go for cervical cancer screening, low perception of the risk of being susceptible to cervical cancer, fear of cervical cancer, distance to the health facility and lack knowledge of the importance of cervical cancer screening.</p><p><strong>Conclusions: </strong>This study underscores the need for capacity building among healthcare workers and facility upgrades at primary health care centers as well as awareness creation in the community as keys to improving uptake of cervical cancer screening.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1099"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning-based lung cancer classification of CT images.","authors":"Mohammad Khalid Faizi, Yan Qiang, Yangyang Wei, Ying Qiao, Juanjuan Zhao, Rukhma Aftab, Zia Urrehman","doi":"10.1186/s12885-025-14320-8","DOIUrl":"10.1186/s12885-025-14320-8","url":null,"abstract":"<p><p>Lung cancer remains a leading cause of cancer-related deaths worldwide, with accurate classification of lung nodules being critical for early diagnosis. Traditional radiological methods often struggle with high false-positive rates, underscoring the need for advanced diagnostic tools. In this work, we introduce DCSwinB, a novel deep learning-based lung nodule classifier designed to improve the accuracy and efficiency of benign and malignant nodule classification in CT images. Built on the Swin-Tiny Vision Transformer (ViT), DCSwinB incorporates several key innovations: a dual-branch architecture that combines CNNs for local feature extraction and Swin Transformer for global feature extraction, and a Conv-MLP module that enhances connections between adjacent windows to capture long-range dependencies in 3D images. Pretrained on the LUNA16 and LUNA16-K datasets, which consist of annotated CT scans from thousands of patients, DCSwinB was evaluated using ten-fold cross-validation. The model demonstrated superior performance, achieving 90.96% accuracy, 90.56% recall, 89.65% specificity, and an AUC of 0.94, outperforming existing models such as ResNet50 and Swin-T. These results highlight the effectiveness of DCSwinB in enhancing feature representation while optimizing computational efficiency. By improving the accuracy and reliability of lung nodule classification, DCSwinB has the potential to assist radiologists in reducing diagnostic errors, enabling earlier intervention and improved patient outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1056"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRCA cascade counselling and testing in Italy: current position and future directions.","authors":"Silvia Costanzo, Lea Godino, Simona De Summa, Tommaso Maria Marvulli, Maurizio Genuardi, Maria Luisa Di Pietro, Emanuela Lucci Cordisco, Daniela Turchetti, Sara Miccoli, Giuseppe Deledda, Giovanna Fantoni, Valeria Viassolo, Oronzo Brunetti, Raffaele De Luca, Maria Digennaro, Francesca Romito, Maria Campanella, Margherita Patruno","doi":"10.1186/s12885-025-14419-y","DOIUrl":"10.1186/s12885-025-14419-y","url":null,"abstract":"<p><strong>Background: </strong>Genetic testing has led to a considerable enhancement in the ability to identify individuals at risk of Hereditary Breast and Ovarian Cancer syndrome related to BRCA1/2 pathogenic variants, thus necessitating personalised prevention programs. However, barriers related to intrafamilial communication, privacy regulations, and genetic information dissemination hinder preventive care, particularly in Italy, where legal constraints limit the disclosure of genetic risks to at-risk relatives. This study examines the relationship between BRCA1/2 carriers' communication challenges and three factors: cancer status, comprehension of genetic information, and the genetic counseling pathway accessed (Traditional Genetic Counseling, TGC vs. Mainstream Cancer Genetics, MCG).</p><p><strong>Methods: </strong>This multicenter, prospective, observational study included 277 BRCA1/2 carriers (probands and relatives) aged 18-80 from various Italian centers. Participants completed a sociodemographic form, a self-administered survey, and psychological assessments (Impact of Event Scale, IES and Distress Thermometer, DT). Categorical variables were compared using Pearson's Chi-squared test or Fisher's exact test based on sample size and expected frequencies, whereas continuous variables were analyzed using the Wilcoxon rank-sum test because of non-normal data distribution.</p><p><strong>Results: </strong>Among the 277 carriers (115 probands, 162 relatives), 79.4% received TGC and 20.6% MCG. The cancer prevalence was higher in probands (83%) than in relatives (22%). The probands exhibited greater psychological distress (higher IES and DT scores), and cancer-affected relatives had higher distress levels than healthy relatives (p = 0.008). While no severe psychological distress or PTSD was found, distress was more associated with cancer diagnosis than genetic status. Genetic comprehension was significantly higher in relatives (p = 0.007) and in those who underwent TGC compared to MCG (p < 0.001). TGC carriers also better understood genetic risks and management strategies (p < 0.001).</p><p><strong>Conclusions: </strong>Psychological distress and genetic comprehension significantly influenced the communication. TGC enhances understanding more effectively than MCG, highlighting the need for tailored support for both carriers and healthcare professionals to improve cascade counseling and testing rates, and cancer prevention. As we look into the future, we need to critically approach MCG, and determine how to address carriers understanding and prevention needs and reincorporate a more comprehensive genetic risk assessment into the MCG model.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1044"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer mortality in Romania: trends, regional and rural-urban inequalities, and policy implications.","authors":"John W Carew, Silviu Calin Radulescu, Li Zhang, Carmen Ungurean, Cristian Calomfirescu, Florentina Furtunescu, Amr S Soliman","doi":"10.1186/s12885-025-14090-3","DOIUrl":"10.1186/s12885-025-14090-3","url":null,"abstract":"<p><strong>Background: </strong>Romania has the third highest preventable mortality rate in the European Union that is more than double the average rate in the European Union in 2018. Breast cancer (BC) is a significant driver of global preventable mortality but a few studies from Romania have quantified the degree to which BC influences mortality and morbidity. This study aimed to determine differences in BC mortality between Romania and the European Union. The study also examined urban/rural BC mortality across the eight regions of Romania.</p><p><strong>Methods: </strong>Age-standardized BC mortality rates among women were calculated by urban/rural places of residence and by subnational region for 2000-2020, using data provided by the Romanian National Center for Statistics in Public Health, National Institute of Public Health. Age-standardized all-cause, all-cancer, and BC mortality rates were explored for Romania and the European Union for 2000-2017, using data obtained from Eurostat. Urban and rural age-standardized BC mortality rates among women were compared across regions of Romania to national and European rates to examine differences in BC mortality across the country and between urban and rural areas. Joinpoint Trend Analysis was employed to further analyze patterns in mortality rates.</p><p><strong>Results: </strong>Age-standardized national BC mortality rate in Romania decreased from 39.60/100,000 women in 2000 to 38.35/100,000 women in 2020, however rates increased in several regions of the country. While BC mortality rates decreased more in urban areas (by 11.1%) than in rural areas (by 1.6%), urban areas still had a higher BC mortality (46.24/100,000 women in 2020) than rural areas (29.37/100,000 women in 2020) throughout the study period.</p><p><strong>Conclusion: </strong>The higher BC mortality in Romania compared to other countries in the European countries, the higher mortality rates in urban than rural areas, and the regional variation in mortality rates call for future studies to investigate the possible health care system and care seeking behaviors and the environmental determinants that may have contributed to observed mortality profile. Improving the quality of incidence data in the country through efficient cancer registries could also lead to a better understanding of the variation in mortality rates, which is the premise for more targeted health policies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1038"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined association of systemic inflammatory response index and prognostic nutritional index with survival among US cancer survivors.","authors":"Bingqing Luo, Xiaoyan Tan, Lin Chen, Kang Zhou, Shifeng Lou","doi":"10.1186/s12885-025-14509-x","DOIUrl":"10.1186/s12885-025-14509-x","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation and nutritional status play critical roles in determining clinical outcomes across multiple disease entities, particularly malignancies. Significantly, these two pathophysiological factors exhibit dynamic interplay through shared pathobiological mechanisms. This study sought to investigate the independent and combined prognostic capacity of the systemic inflammatory response index (SIRI) and prognostic nutritional index (PNI) in predicting all-cause, cancer-specific, and non-cancer mortality among cancer survivors.</p><p><strong>Methods: </strong>Utilizing the National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2018, 3,289 adult cancer survivors (weighted population: 20,795,493) were analyzed. Restricted cubic splines (RCS) delineated mortality risk nonlinearity. Survival trajectories were assessed via Kaplan-Meier (KM) analysis with complex survey adjustments. Weighted Cox proportional hazards models quantified independent and joint associations.</p><p><strong>Results: </strong>Eight hundred seventy-four deaths were identified over a median follow-up of 6.5 years. By RCS analyses, SIRI exhibited a linear association with all-cause mortality, whereas PNI demonstrated a nonlinear relationship with all-cause mortality. Weighted Cox regression analysis demonstrated increased all-cause, cancer-specific, and non-cancer mortality risks in cancer survivors with high-SIRI or with undernutrition (PNI ≤ 48). Joint analysis showed that cancer survivors with concurrent high-SIRI and undernutrition had the highest risk for all-cause (HR 3.169, 95%CI 2.324-4.321), cancer-specific (HR 2.578, 95%CI 1.308-5.080) and non-cancer (HR 2.197, 95%CI 1.480-3.261) mortality, respectively, relative to the reference group with concurrent low-SIRI and PNI > 48. Subgroup and interaction analysis confirmed the stability of the core results.</p><p><strong>Conclusion: </strong>SIRI and PNI emerged as independent prognostic predictors with synergistic mortality prediction capacity in cancer survivors. Cancer survivors with concurrent high level of systemic inflammation and poor nutritional status was associated with the highest mortality risk for all-cause, cancer-specific, and non-cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1114"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-machine learning model based on radiomics features to predict prognosis of muscle-invasive bladder cancer.","authors":"Bin Wang, Zijian Gong, Peide Su, Guanghao Zhen, Tao Zeng, Yinquan Ye","doi":"10.1186/s12885-025-14279-6","DOIUrl":"10.1186/s12885-025-14279-6","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to construct a survival prognosis prediction model for muscle-invasive bladder cancer based on CT imaging features.</p><p><strong>Materials and methods: </strong>A total of 91 patients with muscle-invasive bladder cancer were sourced from the TCGA and TCIA dataset and were divided into a training group (64 cases) and a validation group (27 cases). Additionally, 54 patients with muscle-invasive bladder cancer were retrospectively collected from our hospital to serve as an external test group; their enhanced CT imaging data were analyzed and processed to identify the most relevant radiomic features. Five distinct machine learning methods were employed to develop the optimal radiomics model, which was then combined with clinical data to create a nomogram model aimed at accurately predicting the overall survival (OS) of patients with muscle-invasive bladder cancer. The model's performance was ultimately assessed using various evaluation methods, including the ROC curve, calibration curve, decision curve, and Kaplan-Meier (KM) analysis.</p><p><strong>Results: </strong>Eight radiomic features were identified for modeling analysis. Among the models evaluated, the Gradient Boosting Machine (GBM) In the prediction of OS performed the best. the 2-year AUCs were 0.859, 95% CI (0.767-0.952) for the training group, 0.850, 95% CI (0.705-0.995) for the validation group, and 0.700, 95% CI (0.520-0.880) for the external test group. The 3-year AUCs were 0.809, 95% CI (0.704-0.913) for the training group, 0.895, 95% CI (0.768-1.000) for the validation group, and 0.730, 95% CI (0.569-0.891) for the external test group. The nomogram model incorporating clinical data achieved superior results, the AUCs for predicting 2-year OS were 0.913 (95% CI: 0.83-0.98) for the training group, 0.86 (95% CI: 0.78-0.96) for the validation group, and 0.778 (95% CI: 0.69-0.94) for the external test group; for predicting 3-year OS, the AUCs were 0.837 (95% CI: 0.83-0.98) for the training group, 0.982 (95% CI: 0.84-1.0) for the validation group, and 0.785 (95% CI: 0.75-0.96) for the external test group. The calibration curve demonstrated excellent calibration of the model, while the decision curve and KM analysis indicated that the model possesses substantial clinical utility.</p><p><strong>Conclusion: </strong>The GBM model, based on the radiomic features of enhanced CT imaging, holds significant potential for predicting the prognosis of patients with muscle-invasive bladder cancer. Furthermore, the combined model, which incorporates clinical features, demonstrates enhanced performance and is beneficial for clinical decision-making.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1116"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.","authors":"Hai-Bo Sun, Shao-Kang Feng, Xian-Ben Liu, Wen-Qun Xing, Pei-Nan Chen, Duo Jiang, Yang Liu","doi":"10.1186/s12885-025-14472-7","DOIUrl":"10.1186/s12885-025-14472-7","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the association between adjuvant chemotherapy and the survival of cT1b-T2 patients with incidentally discovered positive lymph nodes (cN- but pN+) after esophagectomy for esophageal squamous cell carcinoma.</p><p><strong>Materials and methods: </strong>Esophageal cancer patients in whom positive lymph nodes were incidentally discovered after esophagectomy were enrolled in this retrospective cohort study. Patients were divided into the surgery alone and adjuvant chemotherapy groups. Propensity score matching (1:1) was used to minimize baseline differences.</p><p><strong>Results: </strong>In total, data from 343 patients who were incidentally discovered to have positive lymph nodes after surgery were analyzed. Each group consisted of 107 patients, with no significant difference in the background information between the two groups. There was also no significant difference in the overall survival (P = 0.227) or disease-free survival (P = 0.210) between the groups in the matched overall study population. Notably, in subgroup analysis, The disease-free survival in the adjuvant chemotherapy group was significantly better than that in the operation group alone for patients with pathological stage T3 (P = 0.023). Multivariate analysis showed that male (ref: female, HR = 1.796, 95% CI, 1.013-3.183, P = 0.045) was a significant independent predictive factor for overall survival.</p><p><strong>Conclusion: </strong>Adjuvant chemotherapy may improve survival for patients with cT1b-T2 but pathological T3 stage patients with incidentally discovered node-positive esophageal squamous cell carcinoma.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1060"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.","authors":"Zhengjia Lu, Jiao Yang, Yang Feng, Jia Ming","doi":"10.1186/s12885-025-14451-y","DOIUrl":"10.1186/s12885-025-14451-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Hormone receptor-positive breast cancer is characterized by the expression of estrogen receptor (ER) or progesterone receptor (PR), it is generally associated with less aggressive clinical features and more favorable prognostic outcomes, primarily due to the effectiveness of endocrine therapy. However, the loss of PR expression has been correlated with endocrine resistance and poorer prognosis. To date, there is limited research elucidating the underlying mechanisms distinguishing ER-positive/PR-positive from ER-positive/PR-negative breast cancer. This study aims to investigate the molecular mechanisms associated with these two subtypes and to propose recommendations for precision therapy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Patients and methods: &lt;/strong&gt;Fresh tumor tissues from ER + /PR + patients (n = 5) and ER + /PR- patients (n = 5) were subjected to proteomic analysis to identify differentially expressed proteins. Transcriptomic data were obtained from the TCGA database, encompassing 937 breast cancer patients divided into three subgroups: ER + /PR + (n = 627), ER + /PR- (n = 112), and ER-/PR- (n = 198). Clinical characteristics and prognostic data were collected to analyze disease-specific survival (DSS) and overall survival (OS) across the three subtypes. Differential expression data for both transcripts and proteins were extracted, and Cox regression along with Least Absolute Shrinkage and Selection Operator (LASSO) regression were applied to identify key regulatory genes. A risk scoring formula was employed to classify patients into high-risk and low-risk groups. Kaplan-Meier curves, Gene Set Enrichment Analysis (GSEA), immune cell infiltration analysis, and OncoPredict drug sensitivity predictions were conducted to provide insights into the underlying mechanisms and clinical treatment strategies for this patient cohort. The accuracy of this model was further validated using external GEO datasets (GSE21653, GSE20685, and GSE42568). Additionally, we collected data from 97 hormone receptor-positive breast cancer patients who underwent neoadjuvant chemotherapy at our center between January 2021 and December 2023, assessing their response to chemotherapy using the Miller-Payne score.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the TCGA database, patients with ER + /PR- breast cancer exhibited poorer 5-year DSS and OS compared to those with ER + /PR + status (DSS: P = 0.038; OS: P = 0.052), which was similar to those with ER-/PR- status (DSS: P = 0.47; OS: P = 0.77). 186 differentially expressed proteins (110 up-regulated and 76 down-regulated) were identified based on proteomic analysis. After COX regression and Lasso regression, five key differential genes with prognostic and diagnostic value of ER + /PR + and ER + /PR- patients were finally included, that is HPN, FSCN1, FGD3, LRIG1, and TBC1D7. HPN, FSCN1 and FGD3 can be regarded as a tumor suppressor gene. And LRIG1, and TBC1D7 can be regarded as a risk-associated gene. Patients with high-","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1048"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144538714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}